NCT05319132View on ClinicalTrials.gov

Evaluate DF-003 in ex Vivo Assays Using Peripheral Blood Mononuclear Cell From Subjects With ROSAH Syndrome

RecruitingOBSERVATIONAL
Enrollment

4

Participants

Timeline

Start Date

September 6, 2022

Primary Completion Date

May 6, 2028

Study Completion Date

May 6, 2028

Conditions
Unrecognized Condition
Interventions
OTHER

Adult subjects with ROSAH syndrome

The main objective is to evaluate the ex vivo inhibitory potential of DF-003 on alpha-1 kinase activity.

Trial Locations (5)

35000

NOT_YET_RECRUITING

Service de médecine interne et immunologie clinique, Rennes

49000

NOT_YET_RECRUITING

service de Genetique - Institut de Biologie Santé PBH-IBS, Angers

51000

NOT_YET_RECRUITING

Service D'ophtalmologie, Reims

69004

RECRUITING

Hôpital Nord Croix Rousse, Lyon

75013

RECRUITING

Hôpital de la Pitié Salpétrière, Paris

All Listed Sponsors
lead

Hospices Civils de Lyon

OTHER